Diana Moreno Muñoz

ORCID: 0000-0002-1540-3393
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Venous Thromboembolism Diagnosis and Management
  • Gastrointestinal motility and disorders
  • Central Venous Catheters and Hemodialysis
  • Lung Cancer Research Studies
  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • Gastric Cancer Management and Outcomes
  • Brain Metastases and Treatment
  • Prostate Cancer Diagnosis and Treatment
  • Intraperitoneal and Appendiceal Malignancies
  • Opioid Use Disorder Treatment
  • Cardiovascular Disease and Adiposity
  • Cancer, Stress, Anesthesia, and Immune Response
  • Pituitary Gland Disorders and Treatments
  • Radiomics and Machine Learning in Medical Imaging
  • Prostate Cancer Treatment and Research
  • Hidradenitis Suppurativa and Treatments
  • Pain Management and Opioid Use
  • Ovarian cancer diagnosis and treatment
  • HER2/EGFR in Cancer Research
  • PARP inhibition in cancer therapy
  • Pathogenesis and Treatment of Hiccups
  • Protein Degradation and Inhibitors
  • Myasthenia Gravis and Thymoma
  • Cancer Treatment and Pharmacology

Hospital Universitario Fundación Alcorcón
2019-2023

GEICAM – Spanish Breast Cancer Group
2022

Universidad Rey Juan Carlos
2022

Houston Methodist
2021

Hospital Juan Ramón Jiménez
2013

Objectives Opioid-induced constipation (OIC) can affect up to 63% of all patients with cancer. The objectives this study were assess quality life as well efficacy and safety naloxegol, in cancer OIC. Methods An observational was made a cohort OIC exhibiting an inadequate response laxatives treated naloxegol. sample consisted adult outpatients Karnofsky performance status score ≥50. Patient Assessment Constipation Quality Life Questionnaire (PAC-QOL) the Symptoms (PAC-SYM) applied for 3...

10.1136/bmjspcare-2020-002249 article EN cc-by-nc BMJ Supportive & Palliative Care 2020-05-06

Abstract Purpose Molecular subtyping based on gene expression profiling (i.e., PAM50 assay) aids in determining the prognosis and treatment of breast cancer (BC), particularly hormone receptor (HR)-positive/human epidermal growth factor 2 (HER2)-negative tumors, where luminal A B subtypes have different prognoses treatments. Several surrogate classifications been proposed for distinguishing between subtypes. This study determines accuracy local immunohistochemistry (IHC) techniques...

10.1007/s10549-023-07094-9 article EN cc-by Breast Cancer Research and Treatment 2023-09-29

Naloxegol is a peripherally acting µ-opioid receptor antagonist (PAMORA) for treatment of opioid-induced constipation (OIC). The main objective was to analyse the long-term efficacy, quality life (QOL) and safety naloxegol in patients with cancer real-world study.This one-year prospective study included older than 18 years, active oncological disease who were under opioids pain control Karnofsky≥50 OIC inadequate response laxative (s). All received according clinical criteria. efficacy...

10.1136/bmjspcare-2020-002816 article EN cc-by-nc BMJ Supportive & Palliative Care 2021-03-11

Introduction There is currently no validated score capable of classifying cancer-associated pulmonary embolism (PE) in its full spectrum severity. This study has the EPIPHANY Index, a new tool to predict serious complications cancer patients with suspected or unsuspected PE. Method The PERSEO Study prospectively recruited individuals PE and active receiving antineoplastic therapy from 22 Spanish hospitals. estimation relative frequency θ based on Index categories was made using Bayesian...

10.1371/journal.pone.0266305 article EN cc-by PLoS ONE 2023-05-09

<ns4:p><ns4:bold>Background: </ns4:bold>Colitis is a frequent immune-related toxicity, without any biomarker that may predict its onset. It endoscopically similar to intestinal inflammatory diseases, where fecal calprotectin (FC) used as early-detect relapse. We found contradictory evidence about FC and immunotherapy no prospective study was already published. </ns4:p><ns4:p> <ns4:bold>Methods</ns4:bold>: present an analytical, observational of one year’s duration. analyzed basal, then prior...

10.12688/f1000research.53327.1 preprint EN cc-by F1000Research 2021-07-05

10.1016/j.rpor.2013.03.588 article EN publisher-specific-oa Reports of Practical Oncology & Radiotherapy 2013-06-01

Abstract Background: The incidence of breast cancer brain metastases (BCBM) is estimated to be around 5-15%, but necropsies show a much higher (30-50%). Frecuency BCBM has gradually increase likely as result from advances in systemic treatment that allow more patients live long enough develop BCBM. In general, outcome for with poor, 1-year survival approximately 20%, some patient and tumor characteristics are associated improved behaviour. RegistEM study non-interventional cohort providing...

10.1158/1538-7445.sabcs21-pd4-08 article EN Cancer Research 2022-02-15

ABSTRACT Introduction There is currently no validated score capable of classifying cancer-associated pulmonary embolism (PE) in its full spectrum severity. This study has the EPIHANY Index, a new tool to predict serious complications cancer patients with suspected or unsuspected PE. Method The PERSEO Study prospectively recruited individuals PE and from 22 Spanish hospitals. estimation relative frequency θ based on EPIPHANY Index categories was made using Bayesian alternative for binomial...

10.1101/2022.03.28.22272682 preprint EN cc-by medRxiv (Cold Spring Harbor Laboratory) 2022-04-02

Background: Management of advanced malignant thymoma is very challenging due to the lack evidence from randomized trials. Despite and non-curable status, most patients achieve long survival they usually receive several treatment lines along their disease. There no standard second line, toxicity chemotherapy (CT) should be considered for these survivors. Treatment with somatostatin analogs showed efficacy in refractory recurrent and/or metastatic thymomas.

10.21037/med-22-ab014 article EN Mediastinum 2022-12-01
Coming Soon ...